Cangene announces potential new treatment for hospital-acquired infections

31-Oct-2006

Cangene Corporation reported publication of results from a collaborative research project conducted at Channing laboratories, a research division of Brigham and Women's Hospita. The research assessed the ability of certain peptides identified at Cangene to inhibit surgical wound infections by Staphylococcus aureus bacteria.

According to the company, unlike antibiotics that directly inhibit bacterial growth or destroy the cells, Cangene's peptides may function by enhancing the patient's own immune system so that it can clear an infection. Treatment with the peptides was highly effective in reducing both the number of S. aureus cells found at the wound site and the associated inflammation they cause. These data suggest a novel approach for treating and possibly preventing staphylococcal wound infections in the clinical setting.

Original publication: Antimicrobial Agents and Chemotherapy 2006 Nov; 50(11):3856-60.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances